Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Emerg Infect Dis ; 30(4): 836-838, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38526202

RESUMEN

We conducted a cross-sectional study of Crimean-Congo hemorrhagic fever virus (CCHFV) in northern Tanzania. CCHFV seroprevalence in humans and ruminant livestock was high, as were spatial heterogeneity levels. CCHFV could represent an unrecognized human health risk in this region and should be included as a differential diagnosis for febrile illness.


Asunto(s)
Virus de la Fiebre Hemorrágica de Crimea-Congo , Humanos , Animales , Ganado , Estudios Transversales , Estudios Seroepidemiológicos , Tanzanía/epidemiología
2.
J Gen Virol ; 105(6)2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38861287

RESUMEN

Increased human-to-human transmission of monkeypox virus (MPXV) is cause for concern, and antibodies directed against vaccinia virus (VACV) are known to confer cross-protection against Mpox. We used 430 serum samples derived from the Scottish patient population to investigate antibody-mediated cross-neutralization against MPXV. By combining electrochemiluminescence immunoassays with live-virus neutralization assays, we show that people born when smallpox vaccination was routinely offered in the United Kingdom have increased levels of antibodies that cross-neutralize MPXV. Our results suggest that age is a risk factor of Mpox infection, and people born after 1971 are at higher risk of infection upon exposure.


Asunto(s)
Anticuerpos Neutralizantes , Anticuerpos Antivirales , Monkeypox virus , Mpox , Vacuna contra Viruela , Humanos , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Vacuna contra Viruela/inmunología , Vacuna contra Viruela/administración & dosificación , Adulto , Persona de Mediana Edad , Monkeypox virus/inmunología , Adulto Joven , Anticuerpos Neutralizantes/sangre , Anticuerpos Neutralizantes/inmunología , Mpox/inmunología , Mpox/prevención & control , Femenino , Adolescente , Anciano , Masculino , Protección Cruzada/inmunología , Escocia , Factores de Edad , Pruebas de Neutralización , Niño , Vacunación , Viruela/prevención & control , Viruela/inmunología , Preescolar , Reacciones Cruzadas , Anciano de 80 o más Años
3.
Commun Biol ; 7(1): 937, 2024 Aug 03.
Artículo en Inglés | MEDLINE | ID: mdl-39095591

RESUMEN

Peste des petits ruminants virus (PPRV) is a multi-host pathogen with sheep and goats as main hosts. To investigate the role of cattle in the epidemiology of PPR, we simulated conditions similar to East African zero-grazing husbandry practices in a series of trials with local Zebu cattle (Bos taurus indicus) co-housed with goats (Capra aegagrus hircus). Furthermore, we developed a mathematical model to assess the impact of PPRV-transmission from cattle to goats. Of the 32 cattle intranasally infected with the locally endemic lineage IV strain PPRV/Ethiopia/Habru/2014 none transmitted PPRV to 32 co-housed goats. However, these cattle or cattle co-housed with PPRV-infected goats seroconverted. The results confirm previous studies that cattle currently play a negligible role in PPRV-transmission and small ruminant vaccination is sufficient for eradication. However, the possible emergence of PPRV strains more virulent for cattle may impact eradication. Therefore, continued monitoring of PPRV circulation and evolution is recommended.


Asunto(s)
Enfermedades de las Cabras , Cabras , Peste de los Pequeños Rumiantes , Virus de la Peste de los Pequeños Rumiantes , Animales , Peste de los Pequeños Rumiantes/transmisión , Peste de los Pequeños Rumiantes/virología , Peste de los Pequeños Rumiantes/epidemiología , Bovinos , Virus de la Peste de los Pequeños Rumiantes/inmunología , Virus de la Peste de los Pequeños Rumiantes/fisiología , Cabras/virología , Enfermedades de las Cabras/virología , Enfermedades de las Cabras/transmisión , Enfermedades de los Bovinos/transmisión , Enfermedades de los Bovinos/virología , Enfermedades de los Bovinos/epidemiología , Erradicación de la Enfermedad/métodos
4.
PLoS Negl Trop Dis ; 18(7): e0012297, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38976760

RESUMEN

Le Dantec virus (LDV), assigned to the species Ledantevirus ledantec, genus Ledantevirus, family Rhabdoviridae has been associated with human disease but has gone undetected since the 1970s. We describe the detection of LDV in a human case of undifferentiated fever in Uganda by metagenomic sequencing and demonstrate a serological response using ELISA and pseudotype neutralisation. By screening 997 individuals sampled in 2016, we show frequent exposure to ledanteviruses with 76% of individuals seropositive in Western Uganda, but lower seroprevalence in other areas. Serological cross-reactivity as measured by pseudotype-based neutralisation was confined to ledanteviruses, indicating population seropositivity may represent either exposure to LDV or related ledanteviruses. We also describe the discovery of a closely related ledantevirus in blood from the synanthropic rodent Mastomys erythroleucus. Ledantevirus infection is common in Uganda but is geographically heterogenous. Further surveys of patients presenting with acute fever are required to determine the contribution of these emerging viruses to febrile illness in Uganda.


Asunto(s)
Anticuerpos Antivirales , Rhabdoviridae , Humanos , Uganda/epidemiología , Adulto , Masculino , Femenino , Adolescente , Adulto Joven , Persona de Mediana Edad , Anticuerpos Antivirales/sangre , Niño , Rhabdoviridae/aislamiento & purificación , Rhabdoviridae/genética , Rhabdoviridae/clasificación , Preescolar , Infecciones por Rhabdoviridae/epidemiología , Infecciones por Rhabdoviridae/virología , Infecciones por Rhabdoviridae/veterinaria , Estudios Seroepidemiológicos , Animales , Reacciones Cruzadas , Lactante , Anciano , Filogenia , Ensayo de Inmunoadsorción Enzimática , Metagenómica
5.
Int J Infect Dis ; 137: 118-125, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38465577

RESUMEN

OBJECTIVES: This study aimed to investigate the changing SARS-CoV-2 seroprevalence and associated health and sociodemographic factors in Malawi between February 2021 and April 2022. METHODS: In total, four 3-monthly serosurveys were conducted within a longitudinal population-based cohort in rural Karonga District and urban Lilongwe, testing for SARS-CoV-2 S1 immunoglobulin (Ig)G antibodies using an enzyme-linked immunosorbent assay. Population seroprevalence was estimated in all and unvaccinated participants. Bayesian mixed-effects logistic models estimated the odds of seropositivity in the first survey, and of seroconversion between surveys, adjusting for age, sex, occupation, location, and assay sensitivity/specificity. RESULTS: Of the 2005 participants (Karonga, n = 1005; Lilongwe, n = 1000), 55.8% were female and median age was 22.7 years. Between Surveys (SVY) 1 and 4, population-weighted SARS-CoV-2 seroprevalence increased from 26.3% to 89.2% and 46.4% to 93.9% in Karonga and Lilongwe, respectively. At SVY4, seroprevalence did not differ by COVID-19 vaccination status in adults, except for those aged 30+ years in Karonga (unvaccinated: 87.4%, 95% credible interval 79.3-93.0%; two doses: 98.1%, 94.8-99.5%). Location and age were associated with seroconversion risk. Individuals with hybrid immunity had higher SARS-CoV-2 seropositivity and antibody titers, than those infected. CONCLUSION: High SARS-CoV-2 seroprevalence combined with low morbidity and mortality indicate that universal vaccination is unnecessary at this stage of the pandemic, supporting change in national policy to target at-risk groups.


Asunto(s)
COVID-19 , Adulto , Humanos , Femenino , Adulto Joven , Masculino , Teorema de Bayes , COVID-19/epidemiología , Vacunas contra la COVID-19 , Estudios de Cohortes , Malaui/epidemiología , SARS-CoV-2 , Estudios Seroepidemiológicos , Anticuerpos Antivirales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA